Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors
NCT ID: NCT05235607
Last Updated: 2022-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
60 participants
INTERVENTIONAL
2022-03-01
2023-12-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Personalized DC Vaccine for Lung Cancer
NCT02956551
Personalized DC Vaccine for Postoperative Cancer
NCT04147078
Immune Cell Therapy for Advanced Solid Tumors
NCT07260058
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NCT05528341
Neoantigen-expanded Autologous Immune Cell Therapy
NCT05020119
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tumor antigen-sensitized vaccine and their sensitized T cells
Tumor antigen-sensitized vaccine is administrated, 1- week interval, totally 2 times.
Then, Neo-antigen DC vaccine and their sensitized T cells are administrated, 2-week interval, totally 5 times.
Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration
subcutaneous administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration
subcutaneous administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pathologically diagnosed advanced (stage IV) malignant melanoma, bladder cancer or colorectal cancer with measurable lesions;
* Failed in the previous standard therapy;
* ECOG PS (Eastern Cooperative Oncology Group performance status) score 0-2 points;
* The estimated survival period is ≥3 months;
* Rehabilitate from previous therapy;
* Adequate organ functions;
* Patient's written informed consent;
Exclusion Criteria
* Abnormal coagulation function;
* Contagious diseases, such as HIV, HBV, HCV infection;
* Mental disorders;
* Concomitant tumors;
* Immunological co-morbidities
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sichuan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhen-Yu Ding
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ji-Yan Liu
Role: PRINCIPAL_INVESTIGATOR
Sichuan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West China Hospital
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PITTN2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.